Plasmapheresis plus LOLA in liver failure of children.
Not Applicable
- Conditions
- Health Condition 1: K720- Acute and subacute hepatic failure
- Registration Number
- CTRI/2023/02/049867
- Lead Sponsor
- Institute of Liver and Biliary Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Pediatric Acute Liver Failure as defined by PALF-Study Group
2.5-18 years of age
3.INR > 2
4.Hepatic encephalopathy (defined by West Haven criteria)
5.Ammonia >100mcg/dL
Exclusion Criteria
1.Irreversible neurological injury
2.Previous treatment with LOLA within 48 hours before admission.
3.Acute kidney injury.
4.Acute on chronic liver failure
5.Those not giving consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparison of change in ammonia (baseline to day 3) in the 2 groupsTimepoint: 72 hrs
- Secondary Outcome Measures
Name Time Method Compare the adverse events in the 2 groupsTimepoint: 72 hours;Comparison of improvement in grade of encephalopathyTimepoint: Day 3 and day 7;Comparison of number of episodes of clinically raised intracranial pressure in the 2 groupsTimepoint: 72 hours;Comparison of ONSDTimepoint: 24,48 and 72 hours;Comparison of overall survivalTimepoint: Day 7 and Day 14;Comparison of plasma and dialysate glutamine levels after HVPETimepoint: 72 hours;Comparison of survival with native liver.Timepoint: Day 7 and Day 14;To compare the cumulative requirement of mannitol and propofol in the first 72 hoursTimepoint: 72 hr